ASCO GI 2022 Conference Coverage

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Videos

Playback speed

February 1, 2022

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

G. A. Brooks

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

Feat. V. Morris

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

Y. Y. Janjigian

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

H. K. Sanoff

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

A. Villanueva

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

H. Chong Toh

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Conference Coverage

Login

Login

Join VuMedi

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Highlights on a Multicenter Phase II Study of Neoadjuvant Nivo+/-Relatlimab + CRT in Stage II/III EC/GEJC

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Hypothetical Patient Case: RAI-R Metastatic Differentiated Thyroid C…

ASCO GI 2022 Biliary Cancer Updates

ASCO GI 2022 Updates in HCC

ASCO GI 2022 Pembro +/- Chemo vs. Chemo Alone for PD-L1+ Advanced GC…

ASCO GI 2022 on the Emerging Roles of ctDNA as a Tool in Metastatic …

ASCO GI 2022 on a Quality-Adjusted Time Without Symptoms or Toxicity…

ASCO GI 2022 CRC Cases: Is It Time to De-Intensify Oxaliplatin to Im…

ASCO GI 2022 Results From the PREVAIL ctDNA Study: Liquid Biopsy for…

ASCO GI 2022 Highlights on a Multicenter Phase II Study of Neoadjuva…

[PRIVATE - new ASCO version uploaded] ASCO GI 2022 Updates on the En…

ASCO GI 2022 Review of the Emerging Roles of ctDNA as a Tool for Ear…

ASCO GI 2022 Updates on the Dose-Escalation & Dose-Expansion Study o…

ASCO GI 2022 Phase I/II Study of Regorafenib and Pembrolizumab in Re…

ASCO GI 2022 on Chemo and CRT Neoadjuvant Regimens for Locally Advan…

ASCO GI 2022 Updates on Integrating New Targeted Therapy Into Locore…

ASCO GI 2022 on mFOLFOX6/Bev +/- Nivo for 1L Treatment of mCRC: Phas…

ASCO GI 2022 on Triplet vs. Doublet Systemic Therapy for Advanced Re…

ASCO GI 2022 Updates on FOLFOX + nab-Paclitaxel (FOLFOX-A) in the Tr…

ASCO GI 2022 Updates on IO for Early Stage HCC

ASCO GI 2022 Long-Term Follow-Up of the GERCOR NIPICOL Study: One-Ye…

ASCO GI 2022 Update on NIVO+ Chemo vs Chemo as 1L Treatment for Adva…

ASCO GI 2022 Updates on IMbrave150 Trial: Exploratory Efficacy & Saf…

ASCO GI 2022 Highlights: Host-Related Biomarkers Including Gut Micro…

ASCO GI 2022 Highlights: Clinical Utility of MSI-H Identified on Liq…